RyboDyn closed a $10 million seed financing to accelerate its program for identifying oncology drug targets in the “dark proteome.” The startup’s platform, RyboCypher, combines deep sequencing of non-canonical RNAs with proteome detection to find disease-specific, druggable protein targets present in patient tumors. RyboDyn says its CypherAtlas database includes data from roughly 1,000 patient tumors across 10 cancer indications, along with information on more than 3 million previously uncharacterized RNAs and 80,000 “cryptic” peptides characterized by mass spectrometry, including about 15,000 cancer-specific peptides. The company reported in vitro killing of tumor cells via a cryptic protein target and identified a novel cryptic protein target present in roughly 45% of HER2-negative breast cancer tumors analyzed. The financing is backed by investors including Genedant, SeaX Ventures, SOSV, Swell VC, Massive Tech Ventures, and P2V. RyboDyn said it is translating discoveries into first-in-class therapies both internally and with pharmaceutical partners. The round highlights a growing appetite for target discovery strategies that look beyond canonical proteins, aiming to expand the “druggable space” through cryptic peptides and non-obvious biology.